Dolutegravir and rilpivirine Approval Status
- FDA approved: No
- Generic name: dolutegravir and rilpivirine
- Company: ViiV Healthcare
- Treatment for: HIV Infection
Dolutegravir and rilpivirine is a single-tablet, two-drug regimen of the approved drugs dolutegravir (Tivicay) and rilpivirine (Edurant) for the maintenance treatment of HIV-1 infection.
Development Status and FDA Approval Process for dolutegravir and rilpivirine
| Date | Article |
|---|---|
| Jun 1, 2017 | EU and US Submissions for Single Tablet Combining Dolutegravir and Rilpivirine Priority Review Voucher Submitted in US with Anticipated Target Action Date of 6 Months |
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.
